ACC 2022 late-breaking trials to address cardiomyopathy, acute MI, flu vaccine and more
The virtual 2022 American College of Cardiology Scientific Session will be held from April 2 to 4, and will feature 25 late-breaking clinical trials, 10 featured clinical research presentations and numerous abstract presentations.
The virtual ACC Scientific Sessions will also include two deep-dive sessions meant to provide further insight into the late-breaking clinical trials.
The ACC announced that late-breaking science to be presented at the session includes:
- the VALOR-HCM trial, which assessed mavacamten (Bristol Myers Squibb) as an alternative to surgical septal myectomy or alcohol ablation for patients with severe symptomatic obstructive hypertrophic cardiomyopathy (HCM);
- the double-blind PACMAN AMI trial of the effects of alirocumab (Praluent, Sanofi/Regeneron) on coronary atherosclerosis assessed by serial multimodality intracoronary imaging in patients with acute MI;
- the double-blind APOLLO trial that evaluated the effects of a short-interfering RNA-targeting lipoprotein(a);
- IVVE, a randomized trial to assess the effects of influenza vaccination on vascular events;
- the PROMPT-HF trial, which sought to improve use of guideline-directed medical therapies among outpatients with HF;
- updated results of treatment from the EXPLORER-LTE cohort of the MAVALTE study in patients with obstructive HCM;
- the 1-year results of the Clasp TR trial that evaluated transcatheter treatment of tricuspid regurgitation (Pascal, Edwards Lifesciences);
- the ADAPT-TAVR trial that compared edoxaban (Savaysa, Daiichi Sankyo) with dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism following transcatheter aortic valve replacement;
- the FLAVOUR trial which compared fractional flow reserve with IVUS-guided PCI for intermediate coronary artery stenosis; and
- the GIPS-IV trial which tested the feasibility of sodium thiosulfate for the preservation of cardiac function after STEMI.
Other late breaking trials to be presented include SODIUM-HF, POISE-3, MITIGATE, TRANSLATE-TIMI 70, SuperWIN, METEORIC-HF, DIAMOND, PROTECT, insights from the Corevalve U.S. Pivotal and SURTAVI trials, GHATI and BIO|GUARD-MI.
The meeting will also showcase two featured clinical research sessions, highlighting a total of 10 individual trials.
Cardiology Today and Healio will be reporting news from the virtual ACC Scientific Session. Stay tuned for news, perspectives and more. Also follow @CardiologyToday on Twitter for continuing updates.
Collapse